Several Options Remain For Cidara’s Flu Candidate After J&J Halts Development

 
• By Ayisha Sharma

Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.  

hands holding up a paper cut-out showing arrows in different directions
Janssen Could Out-License The Asset Or Return It To Cidara • Source: Shutterstock

More from Business

More from Scrip